BACKGROUND: Oncofetal antigen 5T4 is defined by a monoclonal antibody raised against placental trophoblast membranes. Antigen 5T4 is reported to be expressed only on trophoblasts and neoplastic cells and would be a potentially useful marker for neoplastic cells. MATERIALS AND METHODS: We evaluated the expression of 5T4 oncofetal antigen in gastric cancer by immunohistochemistry and investigated whether or not the expression of this antigen is correlated with the prognosis of patients with gastric cancer. RESULTS: The 5T4 antigen was detected in 51.6% of primary gastric cancer (n = 62) and 5T4-reactivity was more frequently observed in carcinoma with lymph node metastasis (p < 0.05). The overall survival of 5T4-positive patients was significantly worse than that of 5T4-negative patients, analyzed by the log-rank test (p < 0.05), although multivariate analysis indicated that 5T4 expression was not an independent prognostic factor. CONCLUSION: The assessment of 5T4 expression may be useful in identifying gastric cancer patients with a poor prognosis.
BACKGROUND: Oncofetal antigen 5T4 is defined by a monoclonal antibody raised against placental trophoblast membranes. Antigen 5T4 is reported to be expressed only on trophoblasts and neoplastic cells and would be a potentially useful marker for neoplastic cells. MATERIALS AND METHODS: We evaluated the expression of 5T4 oncofetal antigen in gastric cancer by immunohistochemistry and investigated whether or not the expression of this antigen is correlated with the prognosis of patients with gastric cancer. RESULTS: The 5T4 antigen was detected in 51.6% of primary gastric cancer (n = 62) and 5T4-reactivity was more frequently observed in carcinoma with lymph node metastasis (p < 0.05). The overall survival of 5T4-positive patients was significantly worse than that of 5T4-negative patients, analyzed by the log-rank test (p < 0.05), although multivariate analysis indicated that 5T4 expression was not an independent prognostic factor. CONCLUSION: The assessment of 5T4 expression may be useful in identifying gastric cancerpatients with a poor prognosis.
Authors: Samuel A Kerk; Kelsey A Finkel; Alexander T Pearson; Kristy A Warner; Zhaocheng Zhang; Felipe Nör; Vivian P Wagner; Pablo A Vargas; Max S Wicha; Elaine M Hurt; Robert E Hollingsworth; David A Tice; Jacques E Nör Journal: Clin Cancer Res Date: 2016-10-25 Impact factor: 12.531
Authors: Helen L Spencer; Angela M Eastham; Catherine L R Merry; Thomas D Southgate; Flor Perez-Campo; Francesca Soncin; Sarah Ritson; Rolf Kemler; Peter L Stern; Christopher M Ward Journal: Mol Biol Cell Date: 2007-05-16 Impact factor: 4.138
Authors: Gemma L Owens; Victoria E Sheard; Milena Kalaitsidou; Daniel Blount; Yatish Lad; Eleanor J Cheadle; Richard J Edmondson; Gurdeep Kooner; David E Gilham; Richard Harrop Journal: J Immunother Date: 2018-04 Impact factor: 4.456
Authors: Mark Jesus M Magbanua; Michael Pugia; Jin Sun Lee; Marc Jabon; Victoria Wang; Matthew Gubens; Karen Marfurt; Julia Pence; Harwinder Sidhu; Arejas Uzgiris; Hope S Rugo; John W Park Journal: PLoS One Date: 2015-10-23 Impact factor: 3.240
Authors: Steven R Pirie-Shepherd; Cory Painter; Pamela Whalen; Pamela Vizcarra; Marc Roy; Jesse Qian; Tania Franks; Tim Coskran; Jon Golas; Shibing Deng; Wenyan Zhong; Eric Tucker; Dena Marrinucci; Hans-Peter Gerber; Eric L Powell Journal: PLoS One Date: 2017-07-20 Impact factor: 3.240